The antidiabetic drug rosiglitazone is in big trouble as the decisions from major regulatory bodies were announced today.
The European Medicines Agency (EMA) announced today that it is recommending … [Read more...]
NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.